Sister Hospital Agreement between MD Anderson in Houston, Texas
Sister Hospital Agreement between MD Anderson in Houston, Texas – the best Oncology Institute in the US, and Sheba Medical Center at Tel Hashomer extended for another five Years
Yesterday, a full day of activities awaited the 8-people delegation from MD Anderson in Houston, Texas, who arrived at the Sheba Medical Center for the signing of a sister hospital agreement, a 5-year extension to the first contract. The visit was hosted by Prof. Shlomo Noy, acting director of the hospital and Vice-President of R&D, and Prof. Amir Onn, the Liaison Officer for the Sister Institution Program.
After a tour of the Sheba campus, Prof. Gidi Rechavi, director of the Sheba Cancer Research Center, presented them with the latest research updates.
During a small ceremony, Prof. Shlomo Noy signed on behalf of the Sheba Medical Center, and Prof. Oliver Bogler, Senior Vice President of Academic Affairs and President GAP, on behalf of MDACC.
Prof. Bogler stressed the importance of having Sheba as a partner in the region and talked about the wonderful cooperation, including 12 ongoing, joint research projects.
Prof. Noy expressed his appreciation for the continuation of the agreement and impressed the guests with the mentioning of two major events in 2015/16:
- Tel Hashomer Ltd., the technology transfer company of the Sheba Medical Center, Boston Scientific, MEDX Ventures Group and Intellectual Ventures (Bill Gates' Investment Company) won the tender to operate a technological incubator of the Israeli Chief Scientist. The incubator is specialized in the field of medical equipment and digital medicine and was founded in exceptional and close cooperation built by these four partners over a long period of time.
- Prof. Gal Markel and Prof. Jacob Schachter from Sheba's Ella Institute for treatment and research of melanoma and skin cancer have succeeded in isolating an antibody that will be used as the basis for treatment of advanced cancer patients. The medical company "MERCK" has purchased the biomed company cCAM Biotherapeutics, which developed the product together with Sheba Medical Center. MERCK'S major development is now done in the US, some here in Israel.
Prof. Bogler expressed his interest in these two events and regards it as a potential cooperation opportunity.
The ceremony was followed by a presentation of Prof. Yehuda Adler, head of the Talpiot Medical Leadership Program. Talpiot is the tool through which the hospital seeks to produce the future medical leaders of tomorrow and to meet Israeli society's critical healthcare needs.
